1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,166 | 0,187 | 10.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 01.04. | SinoMab BioScience Announces First Patient Dosed in China Phase II Trial of SM17 for Atopic Dermatitis | 1 | AASTOCKS | ||
| 01.04. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF SM17 FOR ATOPIC DERMATITIS IN CHINA | - | HKEx | ||
| 31.03. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 31.03. | SINOMAB BIO-B (03681): RESIGNATION OF NON-EXECUTIVE DIRECTORS | - | HKEx | ||
| 25.03. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT TOPLINE RESULTS FROM PHASE 1 BRIDGING STUDY FOR ROUTE OF ADMINISTRATION CONVERSION OF SM17 IN CHINA | - | HKEx | ||
| 24.03. | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | - | HKEx | ||
| 24.03. | SinoMab BioScience Limited: SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement | 299 | JCN Newswire | HONG KONG, Mar 24, 2026 - (ACN Newswire) - SinoMab BioScience Limited ('SinoMab' or the 'Company', together with its subsidiaries, the 'Group' stock code: 03681.HK) is pleased to announce its annual... ► Artikel lesen | |
| 23.03. | SINOMAB BIO-B (03681): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025; AND CHANGE IN USE OF PROCEEDS | 2 | HKEx | ||
| 12.03. | SINOMAB BIO-B (03681): CONNECTED TRANSACTION - TERMINATION OF LEASE AGREEMENT | - | HKEx | ||
| 10.03. | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | - | HKEx | ||
| 24.02. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT IND APPROVAL FOR IBD OF SM17 BY NMPA | - | HKEx | ||
| 18.02. | XFRA NEW INSTRUMENTS AVAILABLE ON 18.02.2026 | 1.306 | Xetra Newsboard | The following instruments on XETRA do have their first trading 18.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.02.2026
Aktien
1 US02083X2027 Alpine Income Property... ► Artikel lesen | |
| 11.12.25 | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT IND APPLICATION FOR SM17 ACCEPTED BY NMPA CDE | - | HKEx | ||
| 14.10.25 | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT FIRST COHORT OF HEALTHY SUBJECTS DOSED WITH SUBCUTANEOUS FORMULATION OF SM17 IN A BRIDGING STUDY IN CHINA | - | HKEx |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| EVOTEC | 4,530 | +0,09 % | Evotec-Aktie profitiert von Milliarden-Deal: Gilead kauft Tubulis | Der US-Pharmakonzern Gilead setzt seine Einkaufstour im Biotech-Sektor fort und übernimmt das deutsche Krebsforschungsunternehmen Tubulis für bis zu fünf Milliarden Dollar. Die Transaktion zeigt, wie... ► Artikel lesen | |
| BIONTECH | 81,40 | -0,06 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,670 | +1,86 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| BEAM THERAPEUTICS | 27,450 | +4,21 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
SINOMAB BIOSCIENCE LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,022 (+12,43 %) liegt der Kurs bei 0,199 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.